RICHMOND, British Columbia, July 25, 2005 (PRIMEZONE) -- BioCurex Inc. (Pink Sheets:BOCX) wishes to advise its shareholders of the availability of an independent research report on the Company prepared by Emergent Growth Analytics Research. The report strictly represents the views of the analyst concerning Biocurex. The report is available at http://www.smallcapnetwork.net/bocx_signup.html concerning BioCurex. The information may be of interest to the shareholders of BioCurex and the link to the report is provided for their benefit.
BioCurex is advancing in its corporate goals and will provide the appropriate updates. The Company is pleased to note that it is receiving increasing attention for its patented/proprietary technology for the detection of many types of cancer with a basic blood test.
BioCurex has signed a licensing agreement with Abbott Laboratories for BioCurex's RECAF Cancer technology as outlined in a joint press release dated March 29, 2005. The release noted that the receptor for alpha-fetoprotein, RECAF has emerged as a potential biomarker that may be useful in the development of new cancer diagnostics tests. RECAF is found on malignant cells from a variety of cancer cell types but is absent in most normal and benign cells. Preliminary studies from the investigators at BioCurex have reported a high level of clinical sensitivity and specificity for RECAF in many of the most common cancers, including prostate, breast, colorectal, lung and others. Abbott's goal is to further develop this technology, incorporating it into future tests on their ARCHITECT(r) system, for use in cancer diagnosis and monitoring.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, imaging and therapy. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To read more about the Company, please visit the News section in our web site (www.biocurex.com).
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.